H. Lundbeck A/S- (OTCMKTS:HLUYY) was upgraded by Zacks Investment Research from a “hold” rating to a “strong-buy” rating in a research report issued to clients and investors on Saturday. The firm presently has a $58.00 target price on the stock. Zacks Investment Research‘s price target would suggest a potential upside of 11.57% from the company’s current price.

According to Zacks, “H. Lundbeck A/S is an international pharmaceutical company engaged in the research and development, production, marketing and sale of pharmaceuticals across the world. Its products are targeted at disorders like depression and anxiety, schizophrenia, insomnia, Huntington’s, epilepsies, Alzheimer’s and Parkinson’s diseases. The Company is involved in the development of new and improved drugs for the treatment of psychiatric and neurological disorders. H. Lundbeck A/S is headquartered in Copenhagen, Denmark. “

Shares of H. Lundbeck A/S- (OTCMKTS HLUYY) opened at $51.99 on Friday. H. Lundbeck A/S- has a 52-week low of $40.70 and a 52-week high of $66.67. The company has a debt-to-equity ratio of 0.07, a quick ratio of 1.13 and a current ratio of 1.36. The stock has a market capitalization of $10,347.51, a P/E ratio of 26.94, a price-to-earnings-growth ratio of 1.36 and a beta of 0.17.

H. Lundbeck A/S- (OTCMKTS:HLUYY) last issued its quarterly earnings data on Wednesday, November 8th. The company reported $0.73 earnings per share (EPS) for the quarter. H. Lundbeck A/S- had a return on equity of 30.48% and a net margin of 15.07%. equities research analysts predict that H. Lundbeck A/S- will post 2.44 EPS for the current year.

COPYRIGHT VIOLATION WARNING: This piece of content was published by Watch List News and is owned by of Watch List News. If you are viewing this piece of content on another domain, it was stolen and republished in violation of U.S. & international trademark and copyright legislation. The original version of this piece of content can be accessed at https://www.watchlistnews.com/h-lundbeck-a-s-hluyy-upgraded-by-zacks-investment-research-to-strong-buy/1817382.html.

About H. Lundbeck A/S-

H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and schizophrenia.

Get a free copy of the Zacks research report on H. Lundbeck A/S- (HLUYY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for H. Lundbeck A/S- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for H. Lundbeck A/S- and related companies with MarketBeat.com's FREE daily email newsletter.